[KO Validated] Anti-SUGP2 Rabbit Polyclonal Antibody for WB, ELISA - Q8IX01

Core Product Specifications and Parameters

Biological Background: SUGP2 Function and Localization

• SUGP2 (SURP and G-patch domain-containing protein 2), also known as SFRS14 or SRFS14, is a nuclear protein that may play a role in mRNA splicing.
• It contains SURP and G-patch domains, characteristic of splicing-related proteins, and is classified as an arginine/serine-rich splicing factor.
• The protein is detected in adult testis, and in fetal brain and kidney, suggesting tissue-specific roles in these organs.
• Subcellular localization is primarily nuclear, consistent with its putative involvement in pre-mRNA processing.
• SUGP2 undergoes post-translational modifications, including phosphorylation and ubiquitin-like conjugation (isopeptide bond formation), which may regulate its activity.
• According to UniProt, alternative splicing generates multiple isoforms, contributing to functional diversity.
• SUGP2 has been identified in large-scale proteomic studies as part of the human reference proteome.

Experimental Guidance and Technical Tips

• The immunogen corresponds to an internal region (aa 500-700) of human SUGP2; when designing experiments, ensure that the epitope is present in your target isoform.
• The antibody has been validated by knockout (KO) in human cells, making it particularly reliable for Western blotting in these backgrounds; consider using a matched KO cell lysate as a negative control.
• For Western blot, a band at approximately 120 kDa is expected; pre-stained markers and proper blocking are recommended to minimize non-specific binding.
• While validated for ELISA, optimal dilution conditions should be determined using the relevant sample matrix; cross-reactivity with mouse SUGP2 allows for testing in murine models.
• As a polyclonal antibody, it may recognize multiple SUGP2 isoforms; take this into account when interpreting band patterns.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio offers diagnostic manufacturers and research laboratories streamlined access to validated antibody pairs, optimized mono/polyclonal antibodies, and bulk ancillary reagents. This anti-SUGP2 polyclonal antibody supports splicing mechanism studies and biomarker development, and we can assist with sourcing rare-target raw materials for your IVD applications—bridging the gap from concept to clinic.